CANDEL THERAPEUTICS, INC. Gain (Loss) on Disposition of Assets
CANDEL THERAPEUTICS, INC. (CADL) reported Gain (Loss) on Disposition of Assets of -$306.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. gain (loss) on disposition of assets for the quarter ending 2025-12-31 was $33.00K.
- CANDEL THERAPEUTICS, INC. gain (loss) on disposition of assets for the quarter ending 2025-09-30 was -$300.00K.
- CANDEL THERAPEUTICS, INC. gain (loss) on disposition of assets for the quarter ending 2024-12-31 was $0.00.
- CANDEL THERAPEUTICS, INC. gain (loss) on disposition of assets for the quarter ending 2024-09-30 was $0.00.
- CANDEL THERAPEUTICS, INC. gain (loss) on disposition of assets for fiscal 2025 was -$306.00K.
- CANDEL THERAPEUTICS, INC. gain (loss) on disposition of assets for fiscal 2024 was $0.00.
- CANDEL THERAPEUTICS, INC. gain (loss) on disposition of assets for fiscal 2023 was -$79.00K.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$267.00K derived: sum of 2 quarters · filed 2026-03-12 | -$306.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | -$300.00K 10-Q · filed 2025-11-13 | -$339.00K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | -$11.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | -$2.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | -$2.00K derived: sum of 3 quarters · filed 2025-03-13 | -$5.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | -$2.00K derived: sum of 2 quarters · filed 2025-03-13 | -$5.00K derived: sum of 3 quarters · filed 2025-03-13 | -$5.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$5.00K derived: sum of 2 quarters · filed 2025-03-13 | -$5.00K derived: sum of 3 quarters · filed 2025-03-13 | -$79.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$3.00K derived: sum of 2 quarters · filed 2024-11-14 | -$77.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$74.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$74.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |